J P Morgan Chase & Co Analysts Give Roche (ROG) a CHF 290 Price Target

J P Morgan Chase & Co set a CHF 290 price target on Roche (VTX:ROG) in a report issued on Thursday. The firm currently has a buy rating on the healthcare company’s stock.

Several other research analysts have also commented on the stock. Goldman Sachs Group set a CHF 325 price target on shares of Roche and gave the stock a buy rating in a research note on Monday, September 11th. Berenberg Bank set a CHF 260 target price on shares of Roche and gave the company a neutral rating in a research note on Monday, November 20th. Credit Suisse Group set a CHF 300 target price on shares of Roche and gave the company a buy rating in a research note on Monday, September 11th. set a CHF 203 target price on shares of Roche and gave the company a sell rating in a research note on Friday, October 20th. Finally, Deutsche Bank set a CHF 254 target price on shares of Roche and gave the company a neutral rating in a research note on Friday, October 20th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average target price of CHF 261.84.

Roche (VTX ROG) opened at CHF 244.10 on Thursday. Roche has a 12 month low of CHF 226.10 and a 12 month high of CHF 273.

ILLEGAL ACTIVITY WARNING: “J P Morgan Chase & Co Analysts Give Roche (ROG) a CHF 290 Price Target” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://sportsperspectives.com/2017/12/18/j-p-morgan-chase-co-analysts-give-roche-rog-a-chf-290-price-target.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply